Bromotetrandrine is an P-glycoprotein inhibitor, which were developed and coadministered with chemotherapeutic drugs to overcome the effect of efflux pumps thus enhancing the chemosensitivity of therapeutics.
Isotetrandrine is a small molecule inhibitor, on various aspects of LPS-induced inflammation in vitro and in vivo. It dose-dependently suppresses the severity of LPS-induced ALI by inactivation of MAPK and NF-κB, which may involve the inhibition of tissue